Edgewise Therapeutics shifted to significant profitability in the third quarter of 2026, driven entirely by a massive one-time gain from the divestiture of its muscular dystrophy business. Excluding this transaction, the company remains a clinical-stage entity with no product revenue, focusing resources on its cardiovascular pipeline.
Key Highlights
- The company recognized a $1.348 billion gain from the sale of the sevasemten program to Servier, which closed in July 2026.
- Cash and equivalents surged to $1.74 billion, providing a multi-year runway to support upcoming late-stage clinical trials.
- R&D expenses decreased to $31.6 million from $37.5 million year-over-year as sevasemten costs were eliminated post-sale.
- Lead candidate EDG-7500 remains on track to enter Phase 3 for hypertrophic cardiomyopathy (HCM) by the end of 2026.